KR20030068608A - Pharmaceutical Composition Comprising Cumambrin A for Lowering Level of Blood Glucose - Google Patents

Abstract

PURPOSE: Provided is a pharmaceutical composition comprising cumambrin A or a Chryanthenum boreale M. extract containing cumambrin A as an active ingredient for lowering blood glucose level. The cumambrin A is also used as a health supplement food and a food additive. CONSTITUTION: A pharmaceutical composition for lowering blood glucose level is characteristically composed of cumambrin A or a Chryanthenum boreale M. extract containing cumambrin A, and pharmaceutically acceptable carrier.

Description

Pharmaceutical Composition Comprising Cumambrin A for Lowering Level of Blood Glucose}

The present invention relates to a pharmaceutical composition of cumambrin A, which is useful for lowering blood sugar, and an acid extract containing cumambrin A as an active ingredient.

Synthetic hypoglycemic agents currently used include the use of sulfonylurea-based drugs that promote the secretion of insulin already made by the pancreatic β-cells according to the symptoms of the patient, inhibit the absorption of monosaccharides such as glucose, increase glucose utilization, Biguanide-based drugs that inhibit the production of glucose in the liver, Ciglitazone-based drugs that reduce insulin resistance and increase insulin action, Triglitazone-based drugs that increase insulin activity, and Glucagon antagonists are used. However, these known agents generally have the drawback of showing weak activity or causing frequent side effects.

For example, biguanide-based drugs have serious side effects due to lactic acidosis, and sulfonylurea-based drugs only promote the secretion of insulin already made in the pancreas, which is a problem that affects insulin activity and receptors. There is a known limitation in the treatment of insulin-dependent diabetics.

As described above, known antidiabetic agents are limited in consideration of their administration method due to their side effects and limitations of pharmacological effects.

Therefore, it is very important to develop hypoglycemic agents from natural resources with safety.

The present invention provides a pharmaceutical composition for lowering blood glucose, a dietary supplement, and a food additive containing cumumbrin A or an acid extract containing cumambrin A as an active ingredient, wherein the side effects of the aforementioned conventional hypoglycemic agents are reduced. There is this.

1 is a ¹ H-NMR spectrum of cumambrin A. FIG.

Figure 2 is a graph showing the hypoglycemic effect of acid extracts containing cumambrin A as an active ingredient in diabetic rats induced with straptozotocin.

The present inventors have conducted research to achieve the above object, and as a result, pharmacological pharmacology of cumambrine A for the development of pharmacological and nutritional use of cumambrine A isolated from acidic country or cuminbrine A containing cumambrine A as an active ingredient Investigation of the effects and safety has shown a significant hypoglycemic activity in diabetes mellitus, can be used as cumulbrine A or acid extract containing cumambrine A as an active ingredient, as a dietary supplement and food additives, as well as drugs for hypoglycemia It is convinced that the present invention has been completed.

A first object of the present invention is to provide a pharmaceutical composition for lowering blood sugar, which comprises cumumbrin A or an acid extract containing cumambrin A as an active ingredient, and a pharmaceutically acceptable carrier.

A second object of the present invention is to provide a hypoglycemic dietary supplement containing an acid extract containing cumam brine A as an active ingredient.

A third object of the present invention is to provide a blood glucose lowering food additive containing an acid extract containing cumumbrin A as an active ingredient.

The substance isolated from Chrysanthemum boreale M. according to the invention exhibits a hypoglycemic effect. This material is 5-membered ring, 7-membered ring and five won has been shown to kyumam Dublin A having a guano fluoride sesquioleate terpene lactone structure consisting of a ring, Haruna, Cri by the literature [Phytochemistry 20, 2583, 1981], such as M It was first reported as isolated from Chrysanthemum coronarium and has since been reported to be isolated from Eriocephalus punctulatus by Douglas EAR et al. ( Phytochemistry 31, 2165, 1992). . In the production country, the cumambrin A was first isolated by the present inventors, and it is known that it has an antihypertensive effect (see Korean Patent Application No. 2000-6958).

Mountain country containing cumam brine A is a perennial plant of Asteraceae, grows on mountain or field bank, and its height is 1 ~ 1.5m and many branches are split. The leaves are divided into 5 deep at 5 ~ 7 cm in length with soft hairs on the back. Yellow flowers about 1-1.5 cm in diameter bloom in September-October.

Cumambrin A is repeatedly extracted several times over a long period of time (about 24 hours) with a solvent having a chloroform or ethyl acetate polarity level under reflux of the petals and leaves of the dry ground acid. The filtered extract was concentrated under reduced pressure to obtain a crude extract. This concentrate is purified by silica-gel column chromatography using a concentration gradient of an organic solvent, which is one of the usual purification methods for organic and physiologically active substances, to obtain cumambrine A. If necessary, chromatographic conditions may be changed to obtain a more purified extract.

Isolated cumambrin A is characterized by ultraviolet spectrum, infrared spectrum, nuclear magnetic resonance spectroscopy ( ¹ H NMR, ¹³ C NMR, DEPT 90, 135, ¹ H- ¹³ C COZY, ¹ H- ¹ H COZY) spectrum, mass spectrum data and As a result of analyzing and synthesizing other physicochemical data, it has been found to have a guanolide sesquiterpene lactone structure of the following Chemical Formula 1 in which five ring, seven ring and five ring are fused in order. The compound system in Formula 1 is according to the manner described in J. Williams, JACS 106, 4895-4902 (1984).

The present invention confirmed the nutritional and medical and pharmacological applicability by investigating the activity of a pharmaceutical composition containing cumambrine A for the prevention and treatment of glycemic metabolic diseases.

Investigation of the effect on the hypoglycemic effect of purely isolated cumambrine A or acid extract containing cumambrine A as an active ingredient resulted in an excellent function of reducing blood sugar levels in diabetic rats induced by administration of streptozotocin (STZ). Its action showed a concentration-dependent trend. In addition, it took at least 24 hours to recover the initial blood glucose after the hypoglycemic action, and the tendency to recover was the same regardless of the administration concentration.

As described above, in the present invention, it was confirmed that acid extracts containing cumambrin A or cumambrin A as an active ingredient can lower blood sugar.

The pharmaceutical composition of the present invention comprising cumambrine A having hypoglycemic activity may be formulated in various forms that can be administered orally or parenterally, which are commonly used in the art, and are well known in the art and Process technology can also be used to make dietary supplements and food additives, including cumambrine A.

Cumambrin A extract can be used as a pharmaceutical or edible acceptable carrier for binding agents (e.g. polyvinyl pyrrolidone, hydroxy propyl cellulose), disintegrants (e.g. carboxy methyl cellulose calcium, sodium starch glycolate), diluents ( Eg corn starch, lactose, soybean oil, crystalline cellulose, mannitol), glidants (e.g. magnesium stearate, talc), sweeteners (e.g. white sugar, fructose, sorbitol, aspartame), stabilizers (sodium carboxymethyl cellulose, alpha or Mixed with beta-cyclodextrin, vitamin C, citric acid, white lead), preservatives (e.g. methyl paraoxy benzoate, paraoxy benzoic acid propyl, sodium benzoate) and flavorings (e.g. ethyl vanillin, masking flavor, menthol flavono, herbal flavor) Thus, it can be prepared for preparations such as tablets, syrups, capsules, soft capsules, liquids or injections, and various food and beverages.

<Example

Formulation 1: Tablet

After thoroughly mixing 1-100 mg of cumambrine A, 77 mg lactose, 15 mg crystalline cellulose and 7 mg corn starch, the mixture was compressed into a rotary tableting machine, 7 mm and 15 mm in diameter, weighing 150, 200, 250, 500 mg tablets are obtained.

Formulation 2: Syrup

Dissolve 1 to 100 mg of cumambrine A, 30 g per tablet, 25 g of 70w / v% D-sorbitol and 0.03 g of ethyl p-hydroxybenzoate in 60 ml of warm water. After the solution is cooled, a solution of 0.2 g of flavor in 0.15 g of glycerol and 0.5 g of 96% ethanol is added. The whole mixture is diluted with water to 100 ml.

Formulation 3: Injectable Liquid

Dissolve 1-100 mg of cumambrine A in 8 ml propylene glycol to make 1 ml.

Dosage of cumambrine A may vary depending on factors such as the mode and route of administration, the age, weight and health of the recipient, the condition and extent of symptoms. For use in hypoglycemia, the compounds of the present invention can be administered orally daily, for example, at an active ingredient dosage of about 1 to 100 mg per kg of body weight. Typically dosages of 300 to 500 mg / kg / day, up to 1000 mg / kg / day in 1 to 3 divided doses or sustained release formulations are effective to achieve the desired pharmacological effect.

Hereinafter, the present invention will be described in more detail with reference to Examples. However, these examples are not intended to limit the scope of the present invention.

<Example>

Example 1 Isolation of Extract Containing Cumambrin A as Active Ingredient from Country of Origin

10 L of 90% ethanol (alcohol) was added to 1 kg of dried starch outpost, which was dried well in the shade, and extracted at 35-40 ° C. for 7 days. The filtered extract was concentrated at 40 ° C. under reduced pressure so that the volume of the extract was 1.5 L. 1 L of water was added to the concentrated extract and shaken for 1 hour. The extract was centrifuged (5000 rpm) to separate the supernatant and precipitate. 1 L of 30% ethanol was added to the separated precipitate, followed by shaking for 30 minutes, followed by centrifugation. The precipitate was separated by filtration and dried in vacuo to give an acid extract containing 86 g of cumambrine A as an active ingredient.

The above embodiment is not limited to the country outpost. This embodiment can also be obtained by applying the country of origin, such as petals, stems, leaves.

Example 2: Hypoglycemic Effect of Acid Extracts Containing Cumambrine A as Active Ingredient

As can be seen in Figure 2, the acid extract containing cumambrin A as an active ingredient begins to reduce the blood sugar of streptozotocin (STZ) -induced diabetic rats from 30 minutes after administration, and 6 to 7 after administration. The maximum dropping effect (470 ± 25 → 170 ± 17 mg / dl) was observed over time, and after 7 hours, it gradually recovered and returned to the initial blood sugar at 24 hours. In addition, the hypoglycemic activity tended to be concentration dependent. In addition, the hypoglycemic effect when administered 1 gram / kilogram body weight initially showed a faster and stronger hypoglycemic effect than when administered 100 mg / kilogram body weight, but did not induce hypoglycemia.

Example 3 Cytotoxicity Test of Cumambrin A

To test the cytotoxicity of cumambrin A, blood analysis was performed in mice administered cumumbrin A. As shown in Table 1, cumambrin A of the present invention did not show a toxic effect.

Normal range Control 5mg / kg 10mg / kg 20mg / kg 5 + 5 + 10mg / kg TP 5.8-8.0g / dl 7.1 ± 0.27 6.8 ± 0.39 6.8 ± 0.2 5.9 ± 0.4 6 ± 0 ALB 3.3-5.0g / dl 3.8 ± 0.09 4.0 ± 0.46 4.1 ± 0.3 3.6 ± 0.3 3.5 ± 0 GLO 2.0-3.6 g / dl 3.2 ± 0.16 3.3 ± 0.15 3.2 ± 0.34 3.6 ± 0.04 3.5 ± 0 T-BIL 0.2-1.2 0.2 ± 0.04 0.2 ± 0.04 0.2 ± 0.04 0.2 ± 0 0.2 ± 0 D-BIL 0-0.5 0.27 ± 0.02 0.1 ± 0.1 0.1 ± 0.08 0.1 ± 0.05 0.1 ± 0 I-BIL 0.1-1.2 0.3 ± 0.07 0.3 ± 0.14 0.3 ± 0.11 0.2 ± 0.05 0.1 ± 0 GOT 5-40 units 19.7 ± 2.44 35.3 ± 2.38 40.0 ± 1.0 39.3 ± 3.38 26.5 ± 3.5 GPT 3-35 units 14.3 ± 4.44 22.8 ± 2.13 26.0 ± 2.0 16.5 ± 2.25 14 ± 1 LDH 100-450 units 328.7 ± 16.44 423.8 ± 23.75 354.3 ± 28.38 360.5 ± 21.5 355 ± 2.4 ALP 70-280 units 113.0 ± 10.0 132.0 ± 7.5 165.0 ± 21.0 141.0 ± 14.5 111 ± 9 BUN 10-20mg / dl 16.3 ± 2.22 14.5 ± 2.0 15.6 ± 3.19 18.5 ± 3.98 18.5 ± 3.2 CRE 0.4-1.5 0.8 ± 0.04 0.7 ± 0 0.6 ± 0.2 0.8 ± 0.08 0.7 ± 0 GLU 70-110mg / dl 90.0 ± 3.33 91.5 ± 6 85.8 ± 5.88 90.8 ± 5.75 87.5 ± 4.5 TP: tryptophan, ALB: albumin, GLO: glyoxalase, BIL: bilirubin, GOT and GPT: indicators of hepatotoxicity, LDH: lactic acid dehydrogenase, ALP: alkaline phosphatase, BUN: urea nitrogen in blood, CRE: creatine , GLU: Glucose

As described and demonstrated in detail above, the present invention was found to be able to lower blood sugar by using cumumbrin A or acid extract containing cumambrin A as an active ingredient. In particular, it did not induce hypoglycemia and was shown to be non-histotoxic by undergoing reversible metabolism in the body. This action provides use as a hypoglycemic agent, dietary supplement and food additive without the side effects of conventional hypoglycemic agents.

Claims (1)

A pharmaceutical composition for lowering blood sugar, which comprises cumam brine A or cumam brine A-containing acid extract, and a pharmaceutically acceptable carrier.